TCRR
TCR2 Therapeutics Inc.
NASDAQHealthcareBiotechnologyUS
Company Profile
CEO
Garry E. Menzel
IPO Date
2019-02-14
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
TCR2 Therapeutics Inc.
CEO
Garry E. Menzel
IPO Date
2019-02-14
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 3,370,982 |
| $0.00 |
| 5 Jun 2023 | GADICKE ANSBERT | director, 10 percent owner: | J-Other | Disposed | 3,370,982 | $0.00 |
| 5 Jun 2023 | MPM SunStates Fund, L.P. | 10 percent owner | J-Other | Disposed | 4,158,964 | $0.00 |
| 5 Jun 2023 | MPM BioVentures 2014, L.P. | 10 percent owner | J-Other | Disposed | 4,158,964 | $0.00 |
| 1 Jun 2023 | Cardama Alfonso Quintas | Chief Medical Officer | D-Return | Disposed | 109,459 | $0.00 |
| 1 Jun 2023 | Cardama Alfonso Quintas | Chief Medical Officer | D-Return | Disposed | 70,649 | $0.97 |
| 1 Jun 2023 | Cardama Alfonso Quintas | Chief Medical Officer | D-Return | Disposed | 42,346 | $0.74 |
| 1 Jun 2023 | Cardama Alfonso Quintas | Chief Medical Officer | D-Return | Disposed | 90,720 | $5.88 |
| 1 Jun 2023 | Cardama Alfonso Quintas | Chief Medical Officer | D-Return | Disposed | 114,700 | $5.21 |